Lpwm LLC Purchases New Holdings in Cencora, Inc. (NYSE:COR)

Lpwm LLC bought a new position in Cencora, Inc. (NYSE:COR - Free Report) in the first quarter, according to the company in its most recent disclosure with the SEC. The fund bought 968 shares of the company's stock, valued at approximately $269,000.

A number of other large investors have also added to or reduced their stakes in the stock. Hickory Asset Management Inc. purchased a new position in shares of Cencora during the 4th quarter worth $572,000. Vontobel Holding Ltd. boosted its stake in shares of Cencora by 46.9% during the 4th quarter. Vontobel Holding Ltd. now owns 6,245 shares of the company's stock worth $1,403,000 after acquiring an additional 1,995 shares during the last quarter. Portfolio Design Labs LLC boosted its stake in shares of Cencora by 76.9% during the 4th quarter. Portfolio Design Labs LLC now owns 11,032 shares of the company's stock worth $2,479,000 after acquiring an additional 4,794 shares during the last quarter. Latitude Advisors LLC purchased a new position in shares of Cencora during the 4th quarter worth $559,000. Finally, WCM Investment Management LLC boosted its stake in shares of Cencora by 99.1% during the 4th quarter. WCM Investment Management LLC now owns 2,116 shares of the company's stock worth $476,000 after acquiring an additional 1,053 shares during the last quarter. Institutional investors own 97.52% of the company's stock.

Insider Buying and Selling at Cencora

In other news, Chairman Steven H. Collis sold 14,579 shares of the business's stock in a transaction dated Tuesday, April 22nd. The shares were sold at an average price of $281.81, for a total value of $4,108,507.99. Following the sale, the chairman now directly owns 315,913 shares in the company, valued at $89,027,442.53. The trade was a 4.41% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, EVP Elizabeth S. Campbell sold 4,127 shares of the business's stock in a transaction dated Monday, March 24th. The stock was sold at an average price of $268.28, for a total transaction of $1,107,191.56. Following the completion of the sale, the executive vice president now owns 14,665 shares in the company, valued at approximately $3,934,326.20. This trade represents a 21.96% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 40,253 shares of company stock worth $11,102,417. Insiders own 10.80% of the company's stock.

Cencora Price Performance

NYSE COR traded up $0.60 on Friday, reaching $289.01. The company had a trading volume of 1,302,615 shares, compared to its average volume of 1,528,602. The company has a quick ratio of 0.54, a current ratio of 0.92 and a debt-to-equity ratio of 16.40. The stock has a market capitalization of $56.02 billion, a PE ratio of 41.11, a price-to-earnings-growth ratio of 1.31 and a beta of 0.58. The firm's 50 day moving average price is $286.29 and its 200 day moving average price is $260.27. Cencora, Inc. has a 12 month low of $218.65 and a 12 month high of $309.35.

Cencora (NYSE:COR - Get Free Report) last announced its quarterly earnings results on Wednesday, May 7th. The company reported $4.42 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $4.07 by $0.35. The company had revenue of $75.50 billion for the quarter, compared to the consensus estimate of $75.41 billion. Cencora had a net margin of 0.46% and a return on equity of 328.62%. Cencora's revenue for the quarter was up 10.3% compared to the same quarter last year. During the same period in the previous year, the firm posted $3.80 EPS. As a group, equities analysts predict that Cencora, Inc. will post 15.37 earnings per share for the current year.

Cencora Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Monday, June 2nd. Shareholders of record on Friday, May 16th were issued a $0.55 dividend. The ex-dividend date was Friday, May 16th. This represents a $2.20 dividend on an annualized basis and a yield of 0.76%. Cencora's dividend payout ratio is currently 25.52%.

Analyst Upgrades and Downgrades

Several research analysts have recently weighed in on the stock. Citigroup lifted their price target on shares of Cencora from $330.00 to $355.00 and gave the stock a "buy" rating in a research note on Thursday, May 8th. Bank of America lifted their price target on shares of Cencora from $270.00 to $285.00 and gave the stock a "neutral" rating in a research note on Friday, April 11th. Wells Fargo & Company upgraded shares of Cencora from an "equal weight" rating to an "overweight" rating and lifted their target price for the company from $274.00 to $337.00 in a research note on Tuesday, June 3rd. Wall Street Zen upgraded shares of Cencora from a "hold" rating to a "buy" rating in a research note on Wednesday, March 12th. Finally, UBS Group lifted their target price on shares of Cencora from $298.00 to $335.00 and gave the company a "buy" rating in a research note on Tuesday, April 29th. One research analyst has rated the stock with a hold rating and ten have issued a buy rating to the company's stock. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $306.91.

Cencora Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.